Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Dermatology (Basel, Switzerland)
|
January 1, 1997
Docetaxel-induced subungual hemorrhage
O Vanhooteghem, J André, A Vindevoghel, et al.
Anti-Cancer Drugs
|
October 19, 2000
Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Régional d'Etude du Cancer Colo-Rectal (Belgium)
C Focan, J Bury, M Beauduin, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
September 1, 1992
Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis: a randomized, single-blind, multicentre study. The Ondansetron International Emesis Study Group
M A Dicato, S Kaasa, E Campora, et al.
Anticancer Research
|
July 1, 1995
Levamisole adds granulocyte toxicity to 5FU-based chemotherapies in adjuvant treatment of Dukes B-C colorectal cancer. A preliminary report
L Longrée, C Focan, J Bury, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1990
Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer
R Paridaens, C Focan, J Michel, et al.
Anticancer Research
|
February 24, 2001
Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer
C Focan, J Bury, M Beauduin, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)
|
June 24, 2000
BRCA1 and BRCA2 mutations in Belgian families with a history of breast and/or ovarian cancer
C Sibille-Hoang, O Froment, A Joos de ter Beerst, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 9, 2002
The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions
A F Ferreira Filho, A Di Leo, M Paesmans, et al.
British Journal of Cancer
|
July 5, 2001
Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial
C Focan, M Beauduin, E Salamon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 21, 1998
Randomized trial of recombinant human interleukin-3 versus placebo in prevention of bone marrow depression during first-line chemotherapy for ovarian carcinoma
L S Hofstra, G B Kristensen, P H Willemse, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Dermatology (Basel, Switzerland)
|
January 1, 1997
Docetaxel-induced subungual hemorrhage
O Vanhooteghem, J André, A Vindevoghel, et al.
Anti-Cancer Drugs
|
October 19, 2000
Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Régional d'Etude du Cancer Colo-Rectal (Belgium)
C Focan, J Bury, M Beauduin, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
September 1, 1992
Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis: a randomized, single-blind, multicentre study. The Ondansetron International Emesis Study Group
M A Dicato, S Kaasa, E Campora, et al.
Anticancer Research
|
July 1, 1995
Levamisole adds granulocyte toxicity to 5FU-based chemotherapies in adjuvant treatment of Dukes B-C colorectal cancer. A preliminary report
L Longrée, C Focan, J Bury, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1990
Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer
R Paridaens, C Focan, J Michel, et al.
Anticancer Research
|
February 24, 2001
Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer
C Focan, J Bury, M Beauduin, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)
|
June 24, 2000
BRCA1 and BRCA2 mutations in Belgian families with a history of breast and/or ovarian cancer
C Sibille-Hoang, O Froment, A Joos de ter Beerst, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 9, 2002
The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions
A F Ferreira Filho, A Di Leo, M Paesmans, et al.
British Journal of Cancer
|
July 5, 2001
Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial
C Focan, M Beauduin, E Salamon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 21, 1998
Randomized trial of recombinant human interleukin-3 versus placebo in prevention of bone marrow depression during first-line chemotherapy for ovarian carcinoma
L S Hofstra, G B Kristensen, P H Willemse, et al.
Page
of 2